NVCR earnings analysis
What we found in NVCR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
NovoCure delivered a strong Q2 operating improvement: revenue rose 16% year over year to $183.6 million, gross margin increased to 78%, and the operating loss narrowed to $10.6 million. International expansion, 18% active-patient growth, and cost efficiencies supported positive adjusted EBITDA of $10.8 million and sharply lower operating cash burn. Offsetting the improved commercial execution, TRIDENT missed its primary endpoint, financial income turned to a $1.9 million expense, and management continues to flag spending, tariff, and supply-chain risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue growth accelerated to $183.6M
- Q2 revenue increased 16% year over year to $183.6 million from $158.8 million, and rose from $174.1 million in Q1 2026. Growth was driven by 18% global active-patient growth, including $16.1 million of international growth and $8.7 million in the U.S.
- Gross margin expanded four percentage points
- Gross margin expanded to 78% from 74% a year earlier as cost of revenue fell 1% to $41.1 million despite patient growth. Cost per active patient per month declined 16%, to $2,483 from $2,970, aided by a $4.9 million tariff refund and $2.8 million of lower array costs.
- Profitability improved materially
- The operating loss narrowed sharply to $10.6 million from $39.5 million, improving operating margin to negative 5.8% from negative 24.9%. Diluted EPS improved to a loss of $0.13 from a loss of $0.36 year over year and from a loss of $0.62 in Q1 2026.
- Active-patient base reached 5,128
- Commercial adoption broadened: total active patients reached 5,128 at June 30, 2026, up 18% from 4,331 a year earlier. Optune Pax contributed 285 U.S. active patients and 418 U.S. new prescriptions during Q2.
- Operating cash burn fell 90% year over year
- Cash usage improved substantially: six-month operating cash outflow was $5.4 million versus $51.6 million in the prior-year period. Capital expenditures were $12.1 million, equal to approximately 3.4% of six-month revenue of $357.6 million.
- Adjusted EBITDA turned positive
- Adjusted EBITDA turned positive at $10.8 million in Q2, compared with a $9.9 million loss a year ago. The $20.7 million improvement reflected a $25.1 million increase in gross profit, partly offset by launch spending.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- TRIDENT failed its primary survival endpoint
- The Phase 3 TRIDENT trial missed its primary overall-survival endpoint: median survival was 17.7 months in the Early Start arm versus 17.5 months in the Maintenance Start arm, with p=0.519. This limits evidence for starting TTFields earlier in newly diagnosed GBM.
- Debt capacity is reduced as spending may rise
- Liquidity remains dependent on execution despite $440.6 million of cash, cash equivalents and short-term investments at June 30, 2026. NovoCure has borrowed $200.0 million under its secured facility, cannot access the Tranche C or D borrowings, and says operating expenses may outpace gross profit over the next several years.
- Tariff benefit may not be sustainable
- Management expects continued tariff volatility through 2026. Q2 cost of revenue benefited from a $4.9 million tariff refund, while the company cautioned that it cannot assure recovery of all tariff amounts paid or avoid longer-term gross-margin effects.
- No material Item 1A risk-factor changes
- The filing states there were no material changes to risk factors disclosed in the 2025 10-K. Accordingly, no new or amended Item 1A risk factors were identified in this Q2 2026 10-Q.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.13
- Gross margin
- 77.6%
- Operating margin
- -5.8%
- Segment
- NovoCure manages its business as one operating segment; total Q2 2026 net revenue was $183.6 million.
What they said about what is next.
The 10-Q contains no quantitative revenue or EPS outlook. Management expects KEYNOTE D58 enrollment to complete by the end of 2026 and anticipates discussions with regulators in coming months on potential LUNAR-2 protocol revisions, but did not restate the prior $690 million-$710 million full-year revenue outlook in this filing.
The filing reads better than the one before it.
What came before.
- 10-Q · April 30, 2026
- NovoCure Limited reported a net revenue of $174.1 million for Q1 2026, marking a 12% increase from $154.99 million in Q1 2025. However, the company faced a net loss of $71.1 million, significantly worse than the loss of…
- 10-K · February 26, 2026
- NovoCure reports record full-year and fourth-quarter 2025 revenue with continued clinical and regulatory progress: the company submitted the final PMA module for Optune Mya in December 2025 (accepted as filed) and…
- 10-Q · October 30, 2025
- Q3 2025 results showed revenue growth to $167,204,000 and improved operating cash flow, but the company remains loss-making with a near-term convertible note maturity and increased secured borrowings. International…
- 10-K · February 27, 2025
- NovoCure positions itself as a global oncology device company focused on commercial adoption of Optune Gio and Optune Lua and extension of TTFields into additional solid tumor indications. 2024 brought multiple clinical…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NVCR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever